
FDA accelerates approval for Alzheimer’s drug
Fox News
U.S. health officials approved an Alzheimer's drug that could slow cognitive decline in some cases but comes with risks.
The approval came after clinical trials that showed the drug slows cognitive decline but also carries the risk of brain swelling and bleeding. Louis Casiano is a reporter for Fox News Digital. Story tips can be sent to louis.casiano@fox.com.
"Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research. "This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease."